Accepted for Publication: August 1, 2011.
Author Contributions: Drs Joseph, Fu, Rothman, Kodl, Lando, and Hatsukami had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. Study concept and design: Joseph, Fu, Rothman, Kodl, Lando, and Hatsukami. Acquisition of data: Joseph, Fu, Lindgren, Rothman, Kodl, and Doyle. Analysis and interpretation of data: Joseph, Fu, Lindgren, Rothman, and Kodl. Drafting of the manuscript: Joseph, Fu, Kodl, and Lando. Critical revision of the manuscript for important intellectual content: Joseph, Fu, Lindgren, Rothman, Kodl, Lando, Doyle, and Hatsukami. Statistical analysis: Lindgren and Kodl. Obtained funding: Joseph, Fu, Rothman, Lando, and Hatsukami. Administrative, technical, and material support: Joseph, Doyle, and Hatsukami. Study supervision: Joseph, Fu, Kodl, and Doyle.
Financial Disclosure: Dr Hatsukami has received funding from Nabi Biopharmaceuticals for conduct of a phase III clinical trial for a nicotine vaccine.
Funding/Support: This work was funded by grant P50 DA013333 (National Cancer Institute/National Institute on Drug Abuse) from the Transdisciplinary Tobacco Use Research Center on Tobacco Exposure Reduction.
Additional Contributions: We thank Greta Friedemann-Sanchez, PhD, for her contributions to the design of the data collection; Stephen Weiss, for cost analysis data; Bonnie Houg, PhD, and Kristen Murphy, for their counseling roles; and Anne Marie Weber-Main, PhD, for her critical review and edit of the manuscript.